Reapplix is a Danish research and development company that specializes in the biological treatment and management of diabetic foot ulcers. Their innovative 3C Patch® System draws on the patient's own blood to provide evidence-based biological wound therapy, which is clinically proven to accelerate the healing of chronic diabetic foot ulcers. Reapplix's business model is supported by high-quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category.